Vaxart, Inc. SEC filings VXRT
Vaxart, Inc. has 1,002 filings in SEC EDGAR's recent list, going back to May 18, 2011. Its latest annual report, Form ARS, was filed on Jun 1, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Nov 5, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Nov 5, 2026 (results of operations). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 424B3 | Prospectus | May 19, 2026 | — |
| S-1/A | Amended registration statement | May 18, 2026 | — |
| S-1 | Registration statement | May 8, 2026 | — |
| 424B5 | Prospectus supplement | May 4, 2026 | — |
| S-3 | Shelf registration | Apr 16, 2026 | — |
| 424B5 | Prospectus supplement | Nov 5, 2025 | — |
| 424B5 | Prospectus supplement | Mar 21, 2025 | — |
| 424B5 | Prospectus supplement | Oct 8, 2024 | — |
| S-8 | Employee stock plan registration | Jul 3, 2024 | — |
| 424B5 | Prospectus supplement | Jun 17, 2024 | — |
| S-8 | Employee stock plan registration | Mar 14, 2024 | — |
| 424B5 | Prospectus supplement | Jan 18, 2024 | — |
| 424B5 | Prospectus supplement | Jun 8, 2023 | — |
| 424B5 | Prospectus supplement | Jun 6, 2023 | — |
| 424B5 | Prospectus supplement | May 9, 2023 | — |
| S-3 | Shelf registration | Mar 17, 2023 | — |
| S-8 | Employee stock plan registration | Oct 24, 2022 | — |
| 424B5 | Prospectus supplement | Sep 16, 2021 | — |
| 424B5 | Prospectus supplement | Sep 16, 2021 | — |
| S-8 | Employee stock plan registration | Jun 21, 2021 | — |
| 424B5 | Prospectus supplement | Oct 13, 2020 | — |
| S-3ASR | Automatic shelf registration | Jul 8, 2020 | — |
| S-8 | Employee stock plan registration | Jul 7, 2020 | — |
| 424B5 | Prospectus supplement | Mar 2, 2020 | — |
| 424B4 | Prospectus | Sep 27, 2019 | — |
| POS AM | Filing | Sep 27, 2019 | — |
| FWP | Free writing prospectus | Sep 25, 2019 | — |
| S-1/A | Amended registration statement | Sep 24, 2019 | — |
| S-1/A | Amended registration statement | Sep 20, 2019 | — |
| S-1 | Registration statement | Sep 11, 2019 | — |
| S-8 | Employee stock plan registration | Apr 24, 2019 | — |
| 424B4 | Prospectus | Apr 10, 2019 | — |
| POS AM | Filing | Apr 10, 2019 | — |
| S-1/A | Amended registration statement | Apr 8, 2019 | — |
| 424B5 | Prospectus supplement | Mar 20, 2019 | — |
| S-3/A | Filing | Mar 14, 2019 | — |
| S-1/A | Amended registration statement | Feb 20, 2019 | — |
| S-1 | Registration statement | Feb 6, 2019 | — |
| S-3/A | Form s-3/a | Dec 27, 2018 | — |
| S-3 | Shelf registration | Dec 20, 2018 | — |
| S-8 | Employee stock plan registration | Jun 7, 2018 | — |
| 424B3 | Prospectus | Jan 3, 2018 | — |
| S-4/A | Form s-4/a | Dec 29, 2017 | — |
| S-4 | Registration for a merger or exchange | Dec 12, 2017 | — |
| S-8 | Employee stock plan registration | Dec 16, 2016 | — |
| 424B5 | Prospectus supplement | Oct 2, 2015 | — |
| 424B2 | Prospectus | Jul 15, 2015 | — |
| S-3 | Shelf registration | Jun 26, 2015 | — |
| 424B5 | Prospectus supplement | Jan 10, 2014 | — |
| 424B5 | Prospectus supplement | Jan 9, 2014 | — |
| S-3/A | Form s-3/a | Oct 9, 2013 | — |
| S-3 | Shelf registration | Aug 13, 2013 | — |
| S-8 | Employee stock plan registration | Apr 24, 2013 | — |
Showing 53 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- VXRT (OTC)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- South San Francisco, CA
- SEC filer status
- Accelerated filer, Smaller reporting company
- SEC CIK
- 72444
- Former names
- Aviragen Therapeutics, Inc. (until Feb 15, 2018); Biota Pharmaceuticals, Inc. (until Apr 13, 2016); NABI BIOPHARMACEUTICALS (until Nov 8, 2012); NABI BIOPHARMACEUTICALS (until Jun 29, 2010); NABI /DE/ (until Feb 14, 2002)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.